IMMUNOME INC

Insider Barchas Isaac sold 10,125 Immunome shares at $26.07—an orderly liquidity move amid a 22.8% monthly rally, not a red flag for investors.

Insider trading at Immunome shows steady, rule‑based moves—buy low, sell high—hinting at confidence while highlighting a long‑term upside amid current valuation gaps.

Insider Barchas Isaac sells 101k IMMUNOME shares at $21.12, raising liquidity amid a 21% weekly gain—watch for supply impact and future plans.

Insider option exercises reveal Immunome’s confidence amid mixed trading—watch for clinical milestones to gauge potential upside.

Insider buying at Immunome signals confidence amid volatility—an insider‑led boost that may hint at future upside for cautious investors.

Insider sales at Immunome show disciplined liquidity planning, not panic – a bullish signal for investors amid strong R&D growth and rising share price.

Insider moves at Immunome: CEO buys 25k shares while COO sells 6k – a liquidity shift, not a bearish sign, amid a strong biotech upside.